Pembrolizumab as First-line Therapy for PD-L1-expressing Lung Cancer

Pembrolizumab when bound to PD1 is believed to block PD1 interactions with PD-L1/PD-L2 and consequently enhances cytotoxic T cell effects on tumor cells (1, 2).